Get the latest news, insights, and market updates on RCUS (Arcus Biosciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
HAYWARD, Calif., December 18, 2025--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, announced that Terry Rosen, Ph.D., chief executive officer, will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will take place on Wednesday, January 14th, 2026, at 3:00 pm PT. Dec 18, 2025 - $RCUS
Why Arcus Biosciences (RCUS) Is Down 15.4% After Halting Key Domvanalimab Cancer Trials And What's Next
Arcus Biosciences recently discontinued the Phase 3 STAR-221 and Phase 2 EDGE-Gastric studies of domvanalimab-based regimens in advanced gastric and esophageal cancers, after an interim analysis found no overall survival benefit versus nivolumab plus chemotherapy, while confirming a broadly similar safety profile. In response, Arcus is reallocating R&D toward its HIF-2α inhibitor casdatifan and early-stage immunology and inflammation programs, signaling a major reshaping of its development... Dec 14, 2025 - $RCUS
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
HAYWARD, Calif., December 12, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc., due to futility. The decision is based on the recommendation from the Independent Data Monitoring Committee (IDMC Dec 12, 2025 - $RCUS
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif., December 09, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 3,600 shares of the Company’s common stock at an exercise price per share of $25.80, which was the cl Dec 9, 2025 - $RCUS
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
HAYWARD, Calif., November 18, 2025--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in December: Nov 18, 2025 - $RCUS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple